Advancing a novel product pipeline of neurology therapies
View Product PipelineAbout
We are a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders.
Our novel product pipeline addresses areas of high unmet medical need, with a focus on epilepsy
Read MoreNews
Xenon to Present at the Jefferies 2020 Virtual Healthcare Conference
June 1, 2020
Xenon Reports First Quarter 2020 Financial Results and Provides Corporate Update
May 21, 2020
Xenon Provides Corporate Update in the Context of COVID-19
March 31, 2020
Xenon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 26, 2020
Xenon Reports 2019 Financial Results and Provides Corporate Update
March 9, 2020
Product Pipeline
* A physician-led, Phase 2 proof-of-concept study is ongoing to examine XEN007 as an adjunctive treatment in pediatric patients diagnosed with treatment-resistant childhood absence epilepsy (CAE).
Investors
Visit our Investor page for News Releases, Annual & Quarterly Reports, Webcasts & Events
View Investor Area
